sb 203580 has been researched along with talaporfin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (talaporfin) | Trials (talaporfin) | Recent Studies (post-2010) (talaporfin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 183 | 10 | 80 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imaizumi, T; Kimura, H; Kobayashi, W; Kubota, K; Kusumi, A; Matsumiya, T; Nakagawa, H; Sakaki, H | 1 |
1 other study(ies) available for sb 203580 and talaporfin
| Article | Year |
|---|---|
Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cycloheximide; Deferoxamine; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Free Radical Scavengers; Genes, fos; Genes, jun; Humans; Imidazoles; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Photochemotherapy; Photosensitizing Agents; Porphyrins; Protein Synthesis Inhibitors; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Siderophores; Vascular Endothelial Growth Factor A | 2007 |